# Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

> **NCT05190523** · PHASE2 · COMPLETED · sponsor: **Gannex Pharma Co., Ltd.** · enrollment: 98 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** ASC42 5 mg
- **DRUG:** ASC42 10 mg
- **DRUG:** ASC42 15 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05190523
- **Lead sponsor:** Gannex Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-06
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-03-13
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190523, "Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05190523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*